XEN 1101

Drug Profile

XEN 1101

Alternative Names: 1OP 2198; VRX 621698; XEN1101

Latest Information Update: 13 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Unknown
  • Developer Xenon Pharmaceuticals
  • Class Antiepileptic drugs; Neuroprotectants; Small molecules
  • Mechanism of Action KCNQ potassium channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Epilepsy

Most Recent Events

  • 07 Nov 2017 Xenon Pharmaceuticals plans to initiate clinical development for rare padiatric forms of epilepsy (Early infantile epileptic encephalopathy type 7)
  • 17 Oct 2017 Xenon Pharmaceuticals plans a phase IIa proof-of-concept trial for Focal seizures in the third quarter of 2018
  • 17 Oct 2017 Phase-I clinical trials in Epilepsy (In volunteers) in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top